VIDEO: How to Use Naturopathic Therapies to Complement Conventional Cancer Treatments
Alternative Medicine and Natural Breast Cancer Treatments in CanadaRegardless of the stage of breast cancer, a patient can benefit from working with a naturopathic doctor that focuses on cancer treatments. There are five stages of breast cancer, though some have more than one variable regarding cancer growth and/or movement. The severity of the cancer is determined by various factors, including:
- Stage (0-4), meaning how big is the tumour and how far has it moved?
- Grade of the tumour, meaning how much is the tumour like a regular cell?
- The hormonal status of the tumour, meaning are there receptors for oestrogen and progesterone on the tumours?
- The HER2 status which indicates if the HER2 protein is present and whether Herceptin immunotherapy will work.
- In depth intake, going over the individual goals that the patient has so that an individualised treatment plan can be created by our naturopathic doctors who have experience with naturally treating hundreds of breast cancer patients.
- Cancer diet planning
- Advanced naturopathic therapies (these individual therapies we can’t tell you about here, according to Health Canada guidelines. Please contact our office if you wish to receive more information).
- Heavy metal testing and chemical carcinogen testing
- Proper detoxification
- The use of supplements for specific cancer treatment
- Pre and post-surgery protocols
- Circulatory tumour cell (CTC), and genetic testing to determine the likelihood of the spread of cancer and genetic mutations*
- These tests are only performed by select naturopathic doctors.
Stage 1 Breast CancerStage 1 is considered an early stage of breast cancer. It is when cancer is evident but contained to only the area where the first abnormal cells began to develop. This stage is divided into two parts: 1A and 1B. Stage 1A breast cancer is when the tumour is 2 centimetres or smaller and has not spread to the lymph nodes. Stage 1B is when lymph nodes have evident cancer with clusters of cells that range from 0.2 millimetres to 2 millimetres. In each level of this stage, no tumour is found in the breast.
TreatmentsChemotherapy is not always used and we have had great success using naturopathic medicine alone to prevent the advancement and movement of stage 1 breast cancer. With standard cancer care, it is common for patients to undergo surgery and radiation, or a combination of the two, however, before any treatments, options can be discussed with us to go over the best overall treatment approach for our patients. To highlight the unique nature of each patient’s treatment plans and experiences, we’ve shared several case studies based on real patients, though their names and identifying qualities have been changed to maintain their privacy.
Stage 2 Breast CancerStage 2 is when breast cancer is growing but contained in the breast or has extended to the nearby lymph nodes. Much like stage 1, this stage is divided into two levels: 2A and 2B. Stage 2A, considered early stage, is when there is no tumour associated with the cancerous cells and fewer than four axillary lymph nodes have active cancer cells, or there is a tumour that is less than 2 centimetres and fewer than four axillary lymph nodes have cancer cells. Stage 2B, considered locally advanced breast cancer, is when the tumour is between 2 centimetres and 5 centimetres and has spread to no fewer than four axillary lymph nodes, or the tumour is larger than 5 centimetres but has not spread to any axillary lymph nodes.
TreatmentsStage 2 breast cancer is often treated with surgery. Radiation therapy is common for this stage if cancer has spread to lymph nodes.
Stage 3 Breast CancerStage 3 is when the breast cancer has extended beyond the immediate region of the tumour and could have invaded nearby lymph nodes and muscles but has not spread to distant organs. The third stage, unlike the first two, is divided into three groups: 3A, 3B and 3C. Stage 3A is when there is no actual tumour associated with the cancerous cells, or the tumour is any size and at least four of the nearby lymph nodes contain cancer. Or, stage 3A is when the tumour is larger than 5 centimetres and clusters of cancer cells found in the lymph nodes are up to 2 millimetres. Additionally, stage 3A is when the tumour is larger than 5 centimetres and cancer has spread to lymph nodes under the arm or near the breastbone. Stage 3B is when cancer has spread to the chest wall or breast skin. It might also have affected up to nine nearby lymph nodes. Stage 3C is when no tumour is found in the breast, or the tumour is any size and cancer might have invaded the chest wall or breast skin, affecting 10 or more lymph nodes under the arm. Or, stage 3C is when lymph nodes containing cancer extend to the collarbone area.
TreatmentsStage 3 breast cancer is usually treated in a variety of ways, including a mastectomy, radiation, chemotherapy or hormone therapy. Oftentimes, patients will have a combination of these treatments and naturopathic therapies as well.
Stage 4 Breast CancerStage 4 breast cancer is when cancer has spread to other areas of the body, such as the liver, lung, bone and brain. This is considered advanced breast cancer that might not always be cured, but it can be controlled for many years.
TreatmentsStage 4 breast cancer treatment often depends on the hormone-receptor status and the HER2 status of cancer cells. It will also depend on where cancer has spread and how it is affecting the patient’s overall health. Treatment can include extensive levels of hormonal therapy, chemotherapy and targeted therapy. Doctors might introduce other treatments when previous therapies stop working.
Where do we go from here?On average, 72 Canadian women and 904 American women will be diagnosed with breast cancer every day. In Canada and the U.S., breast cancer is the most common cancer in women (not considering non-melanoma skin cancers) (Canadian Cancer Society 2017, National Cancer Institute 2018). Due to early detection of disease, and improved therapies, fewer women are dying of breast cancer. However, breast cancer is still the 2nd leading cause of death from women with cancer (Canadian Cancer Society 2017).
Are Natural Breast Cancer Treatments Right for Me?Book an appointment or call our naturopath office today at (204) 808-3632 to discuss potential treatment options. Our experts will guide you in the right direction.
VIDEO: How to Use Naturopathic Therapies to Complement Conventional Cancer Treatments
Want More Technical Information?
How Does Breast Cancer Form?
In order for any cancer to arise, tissues must undergo three phases of cellular changes, called initiation, promotion and progression.
Entails irreversible structural changes to DNA through substances foreign to our body (Rous and Kidd 1941, Mackenzie and Rous 1941).
On the other hand, means that once an initiator has changed the conformation of the DNA, the cells with these changes are now susceptible to the action of promoters. Up until this point, the DNA changes were passed onto daughter cells but the cell line did not display any abnormal behaviour (Rous and Kidd 1941, Mackenzie and Rous 1941). However, once a promotor causes a genetic mutation; the cell begins to exhibit the characteristics of cancer (see our What is Cancer? page for more information).
Typically, our body will sense such abnormal activity and stop the progression of these cells to cancer (Rous and Kidd 1941, Mackenzie and Rous 1941). However, in the last phase of progression, the cell line accumulates more mutations that allow for a tumour to form despite our body’s defences.
How Can We Prevent Breast Cancer?
Toxins cause cancer by modifying DNA irreversibly in the initiation and promotion phases. These DNA changes lead to the proliferation of cells, recruitment of inflammatory cells, more reactive oxygen species that damage DNA, as well as less DNA repair (Coussens and Werb 2002). As such, enhancing the body’s ability to detoxify metals and chemicals transmitted from the environment using chelation, for example, may help prevent or reduce such changes to DNA and cells.
Chemo Can Cause Aggressive Cancer Progression After Treatment
As of 2000, the NIH recommends that patients with breast cancer, after primary treatment with mastectomy or lumpectomy, be given adjuvant chemotherapy (NIH 2000). These chemotherapies include: paclitaxel, docetaxel, doxorubicin, epirubicin, cyclophosphamide, or flourouracil (5-FU). However, these chemotherapy agents cause aggressive return of cancer following treatment (Chrisanthar et al.2008, Hansen et al. 2015, Smith et al. 2006, Takahashi et al. 2013, Végran et al. 2006). Although many mechanisms are implicated in the formation of resistance, resistance mutations typically arise early on in breast stem cells (Dean et al. 2010, Lynch et al. 2006, Yagüe et al. 2007).
As well, the chemo-agent called paclitaxel is a first-line form of conventional treatment for breast cancer (Valvero and Hortobagyi 2003). However, tumours may become resistant to paclitaxel through NF-κB activation and as such, this drug is no longer able to treat advanced stages of breast cancers (Pianetti et al. 2001). Chemotherapy can be a powerful tumour inhibitor but it can cause a deadly backlash of the cancer after treatment that can lead to a more aggressive cancer with metastasis or spread later on (Aldonza, et al. 2017).
Holistic Breast Cancer Treatment to Deal With the Side-Effects of Chemotherapy
Although chemotherapy is a life-saving form of treatment, these drugs often have many side effects. A common side effect includes neurotoxicity, leading to peripheral neuropathy, which can be reduced using IV ALA therapy (Gedlicka et al. 2002 and 2003; Melli et al.2008). Furthermore, up to 50-80% of patients treated with chemotherapy will experience diarrhea (Stein et al. 2010). As such, using ALA prior to chemo-agents like methotrexate helps protect against intestinal toxicity and improve the consistency of stool (Dadhania et al. 2010). IV ALA also helps with cardiotoxicity (Al-Majed et al. 2002, Balachandar et al. 2003) and kidney damage (Malarkodi et al. 2003a, b, c, d; Murugavel and Pari 2004).
Cancer Treatments at Our Centre (International and Local Patients)
All of these naturopathic oncology treatments are available at the Centre For Natural Pain Solutions in Winnipeg, Canada. Out-of-town patients travel to Winnipeg and stay for a length of time in order to receive daily treatments at our centre. Please call our office for an appointment or to receive more information at 1-204-808-1878 or contact us via email using the contact form. We hope to see you at our centre!
Read More to Learn About These Breast Cancer Topics
- Breast Cancer Statistics
- Alternative Medicine and Natural Treatment for Breast Cancer
- Human study showing natural alternatives to chemo superior to chemotherapy in stage 4 breast cancer
- Stage 4 Breast Cancer in Remission Without Use of Chemotherapy: a case from our clinic
- Is This a Natural Cure for Breast Cancer?
- How Cancer Forms
- How Can We Prevent Breast Cancer?
- Chemotherapy can cause aggressive cancer progression after treatment
- Holistic breast cancer treatment to deal with the side-effects of chemotherapy
- Cancer Treatments at Our Centre (International and local patients). Contact our Cancer Clinic
If you’d like to discuss alternative breast cancer therapies for you or a loved one, please contact us today.
VIDEO: How to Use Naturopathic Therapies to Complement Conventional Cancer Treatments
Aggarwal, B. B., Shishodia, S., Takada, Y., et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11: 7490–8.
Al-Majed, A. A., Gdo, A. M., Al-Shabanah, O. A., et al. (2002) Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin. Pharmacol Res. 46(6):499–503.
Aldonza, Mark Borris Docdoc et al. “Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.” Experimental & molecular medicine (2017).
Balachandar, A. V., Malarkodi, K. P., and Varalakshmi, P. (2003) Protective role of DLalpha-lipoic acid against adriamycin-induced cardiac lipid peroxidation. Hum Exp Toxicol. 22(5):249–54.
“Canadian Cancer Society” and “National Cancer Institute of Canada Canadian Cancer Statistics.” (2017) Retrieved from: http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/ ?region=bc
Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature. 420(6917):860–7.
Chrisanthar, R., Knappskog, S., Løkkevik, E., et al. (2008) CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 3(8):e3062.
Dadhania, V. P., Tripathi, D. N., Vikram, A., et al. (2010) Intervention of alpha-lipoic acid ameliorates methotrexate-induced oxidative stress and genotoxicity: A study in rat intestine. Chem Biol Interact. 183(1):85–97.
Dean, M., Fojo, T., and Bates, S. (2005) Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–84.
Duarte, V. M., Han, E., Veena, M. S., et al. (2010) Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKK beta protein of the NF kappa B pathway. Mol Cancer Ther. 9:2665–75.
Fetoni, A. R., Paciello, F., Mezzogori, D., et al. (2015) Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 113(10):1434–44.
Hansen, S. N., Westergaard, D., Thomsen, M. B., et al. (2015) Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumour Biol. 36(6):4327–38.
Gedlicka, C., Scheithauer, W., Schull, B., a et al. (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 20:3359–61.
Gedlicka, C., Kornek, G. V., Schmid, K., et al. (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol. 14:339–40.
Lynch, M. D., Cariati, M., and Purushotham, A. D. (2006) Breast cancer, stem cells and prospects for therapy. Breast Cancer Res. 8:211.
Mackenzie, I. and Rous, P. (1941) The experimental disclosure of latent neoplastic changes in tarred skin. J Exp Med. 73(3):391–416.
Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003a) The influence of lipoic acid on adriamycin induced nephrotoxicity in rats. Mol Cell Biochem. 247:15–22.
Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003b) The influence of lipoic acid on adriamycin-induced hyper-lipidemic nephrotoxicity in rats. Mol Cell Biochem. 247:139–45.
Malarkodi, K. P., Balanchandar, A. V., and Varlakshmi. P. (2003c) Protective effect of lipoic acid on adriamycin-induced lipid peroxidation in rat kidney. Mol Cell Biochem. 247:9–13.
Malarkodi, K. P., Balanchandar, A. V., Sivaprasad, R., et al. (2003d) Prophylactic effect of lipoic acid against adriamycin-induced peroxidative damages in rat kidney. Ren Fail. 25:367–77.
Melli, G., Taiana, M., Camozzi, F., et al. (2008) Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 214(2):276–84. Morré, D. J. and Gilmartin, D. S. (2015) Estimation of the Accuracy of the ONCOblot® Tissue of Origin Cancer Test. West Lafayette, IN: MorNuCo.
Murugavel, P. and Pari, L. (2004) Attenuation of chloroquine-induced renal damage by alpha-lipoic acid: possible antioxidant mechanism. Ren Fail. 26(5):517–24. National Cancer Institute. (2018) Retrieved from: https://www.cancer.gov/types/common-cancers
National Institutes of Health. (2000) Adjuvant Therapy for Breast Cancer, Consensus Development Conference Statement. November 1-3, 2000. Retrieved from: https://consensus.nih.gov/2000/2000AdjuvantTherapyBreastCancer114html.htm
Nahleh Z. Tabbara IA. Complementary and alternative medicine in breast cancer patients. Palliat Support Care. 2003;1:267–273. [PubMed]
Pianetti, S., Arsura, M., Romieu-Mourez, R., et al. (2001) Her-2/neu overexpression induces NF-kappa B via a PI3-kinase/Akt pathway involving calpain-mediated degradation of I kappa-B-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene. 20:1287–99.
Rous, P. and Kidd, J. G. (1941) Conditional neoplasms and subthreshold neoplastic states: A study of the tar tumors of rabbits. J Exp Med. 73(3):365–90.
Shakibaei, M., Kraehe, P., Popper, B., et al. (2015) Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. Bmc Cancer. 15:250.
Shehzad, A., Lee, J., and Lee, Y. S. (2013) Curcumin in various cancers. Biofactors. 39(1):56–68.
Smith, L., Watson, M. B., O’Kane, S. L., et al. (2006) The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol Cancer Ther. 5(8):2115–20.
Standish, LJ. Does Integrative Oncology Improve Survival in Advanced Cancer Patients? Report from the Bastyr Integrative Oncology Research Center (BIORC). 10th International Conference of the Society for Integrative Oncology (ME8659). The Society for Integrative Oncology. October 20-22, 2013, Vancouver, BC.
Stein, A., Voigt, W., and Jordan, K. (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2(1):51–63.
Takahashi, K., Tanaka, M., Inagaki, A., et al. (2013) Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Int J Oncol. 43(6):1985-91.
Thangapazham, R. L., Sharma, A., and Maheshwari, R. K. (2006) Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J. 8(3):E443–9.
Valero, V. and Hortobagyi, G. N. (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 21:959–62.
Végran, F., Boidot, R., Oudin, C., et al. (2006) Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res. 12:5794–800.
Yagüe, E., Arance, A., Kubitza, L., et al. (2007) Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res. 67:1130–7.